Stock comparison
Halozyme Therapeutics
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 67B | HALO |
| Benjamin Graham | 83A | 60C | HALO |
| Philip Fisher | 65B | 75B | HRMY |
| Peter Lynch | 53D | 62C | HRMY |
| Joel Greenblatt | 40D | 28F | HALO |
| Charlie Munger | 80C | 62C | HALO |
| Terry Smith | 84A | 67B | HALO |
Side-by-side metrics
| Metric | HALO | HRMY |
|---|---|---|
| Market cap | $8.1B | $1.75B |
| P/E (TTM) | 24.0x | 11.8x |
| EV/EBIT | 10.2x | 6.4x |
| ROIC (TTM) | 23.65% | 12.5% |
| Gross margin | 81.24% | 76.55% |
| Net margin | 23.13% | 16.2% |
| Revenue CAGR 5y | 33.23% | 29.85% |
| EPS CAGR 5y | -1.98% | 46.45% |
| Debt / Equity | 1.0x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.1Bvs $1.75B+78%
- ROIC (TTM)23.65%vs 12.5%+47%
- Net margin23.13%vs 16.2%+30%
- Revenue CAGR 5y33.23%vs 29.85%+10%
HRMY leads on
- EPS CAGR 5y46.45%vs -1.98%+104%
- Debt / Equity0.2xvs 1.0x+76%
- P/E (TTM)11.8xvs 24.0x+51%
- EV/EBIT6.4xvs 10.2x+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.